Bracco has invested more than 80 million euros to build Hexagon, a new manufacturing facility located next to the 1997 plant which will, when fully operational, triple the production and distribution of one of the leading products from Bracco's research. The new multi-functional building will supply the world with the contrast agent for ultrasound based on microbubbles, which allows real-time diagnosis.
Contrast-Enhanced Ultrasound is a high-sensitivity, non-invasive diagnostic imaging modality free of radiation, capable of enhancing the visibility, and therefore the evaluation, of heart cavities, blood vessels and tissue vascularity. Microbubbles also have enormous potential in the field of precision medicine because they can serve as vectors of pharmaceuticals, activating the temporary opening of the vascular tissue barrier thereby optimizing the therapeutic effect, making it as targeted and effective as possible.
Inauguration day for the new plant - a four-story building characterized by contemporary design and constructed according to sustainability standards - began with a ribbon-cutting ceremony attended by, along with Diana Bracco and Fulvio Renoldi Bracco, Anne Lévy, Director of the FOPH – Federal Office of Public Health; Xavier Magnin, Mayor of Plan-les-Ouates; Monika Schmutz Kirgöz, Ambassador of Switzerland to Italy; Gian Lorenzo Cornado, Ambassador of Italy to Switzerland; Alexandre Epalle, Director General of Economic Development, Research, and Innovation for the Canton of Geneva; and Simona Loizzo, member of the Italian Parliament.
Bracco is an international Group active in more than 100 countries worldwide in the healthcare sector specializing in diagnostic imaging. It has more than 3,800 employees and annual total consolidated revenues of around 1,8 billion euros, 88% of which from international sales. In the Research and Development area, the company invests approximately 10% of reference turnover in the imaging diagnostics and medical devices sectors and has a portfolio comprising more than 2,600 patents.
